Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy

被引:31
作者
Diepeveen, SHA
Verhoeven, GHWE
van der Palen, J
Dikkeschei, BLD
van Tits, LJ
Kolsters, G
Offerman, JJG
Bilo, HJG
Stalenhoef, AFH
机构
[1] Univ Med Ctr Nijmegen, Dept Nephrol 545, NL-6500 HB Nijmegen, Netherlands
[2] Isala Clin, Dept Internal Med, Zwolle, Netherlands
[3] Isala Clin, Dept Clin Chem, Zwolle, Netherlands
[4] Med Spectrum Twente, Dept Epidemiol, Enschede, Netherlands
[5] Univ Med Ctr Nijmegen, Dept Gen Internal Med, NL-6500 HB Nijmegen, Netherlands
来源
NEPHRON CLINICAL PRACTICE | 2004年 / 98卷 / 01期
关键词
end-stage renal disease; lipid peroxides; lag time of in vitro LDL oxidation; oxidized LDL; oxidative stress;
D O I
10.1159/000079921
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim: In patients with end-stage renal disease (ESRD), cardiovascular complications are the main cause of death. Increased oxidative stress is one of the risk factors for enhanced atherosclerosis in this population. Literature data vary partially dependent on differences in methodology. The present study compares three different methods: plasma lipid peroxides, the newly developed measurement of circulating oxidized LDL(Ox-LDL) particles and the frequently used copper-induced LDL oxidation lag time. Methods: We assessed plasma lipid peroxides, circulating Ox-LDL and in vitro copper-induced LDL oxidation lag time in 47 non-diabetic patients with ESRD, at the start of renal replacement therapy, and compared these with 41 age- and sex-matched controls. Results: In ESRD, total cholesterol (4.6 +/- 1.1 vs. 5.6 +/- 0.9 mmol/l; p < 0.001), LDL cholesterol (2.8 +/- 0.8 vs. 3.5 +/- 0.7 mmol/l; p < 0.001) and HDL cholesterol (1.0 +/- 0.3 vs. 1.4 +/- 0.4 mmol/l; p < 0.001) were lower compared to controls. Plasma lipid peroxides were higher (1.1 +/- 0.5 vs. 0.8 +/- 0.5 mu mol/l; p = 0.003) in ESRD. No differences were observed in plasma Ox-LDL (63.1 +/- 62.0 vs. 55.3 +/- 48.0 mg/l). However, due to the lower plasma LDL cholesterol in ESRD, LDL oxidation level was increased in ESRD (7.1 +/- 0.1 vs. 4.2 +/- 0.3%; p = 0.03). LDL lag time was slightly longer (89 +/- 11 vs. 84 +/- 11 min; p = 0.04) in ESRD. There were no significant differences regarding the amount and rate of dienes produced. Conclusions: Elevated levels of lipid peroxides and higher LDL oxidation levels support the theory that ESRD is associated with increased oxidative stress, which may explain the accelerated atherosclerosis. The measured amount of oxidative stress is not reflected by in vitro oxidizability of LDL. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:C3 / C7
页数:5
相关论文
共 32 条
[1]  
Annuk M, 2001, J AM SOC NEPHROL, V12, P2747, DOI 10.1681/ASN.V12122747
[2]  
Annuk M, 2001, CLIN NEPHROL, V56, P308
[3]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[4]   CONTINUOUS MONITORING OF INVITRO OXIDATION OF HUMAN LOW-DENSITY LIPOPROTEIN [J].
ESTERBAUER, H ;
STRIEGL, G ;
PUHL, H ;
ROTHENEDER, M .
FREE RADICAL RESEARCH COMMUNICATIONS, 1989, 6 (01) :67-75
[5]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[6]   Oxidative stress in chronic renal failure [J].
Galle, J .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (11) :2135-2137
[7]  
Galli F, 1999, Contrib Nephrol, V127, P1
[8]   Different effect of antihypertensive drugs on conduit artery endothelial function [J].
Ghiadoni, L ;
Magagna, A ;
Versari, D ;
Kardasz, I ;
Huang, Y ;
Taddei, S ;
Salvetti, A .
HYPERTENSION, 2003, 41 (06) :1281-1286
[9]   Elevated plasma F2-isoprostanes in patients on long-term hemodialysis [J].
Handelman, GJ ;
Walter, MF ;
Adhikarla, R ;
Gross, J ;
Dallal, GE ;
Levin, NW ;
Blumberg, JB .
KIDNEY INTERNATIONAL, 2001, 59 (05) :1960-1966
[10]   The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia [J].
Himmelfarb, J ;
Stenvinkel, P ;
Ikizler, TA ;
Hakim, RM .
KIDNEY INTERNATIONAL, 2002, 62 (05) :1524-1538